Tectonic's study win looks all the more impressive given ... Opportunities to capitalize on a promising drug candidate that takes Wall Street by surprise do not come along that often, so more ...

Shares of Tectonic Therapeutic Inc. (NASDAQ:TECX) closed Jan. 30 at $54.84, up $29.12, or 113%, on what Leerink analyst David Risinger called in his report “the most impressive hemodynamic results we ...

“I had this paper hung up on my wall for the last four years ... the team has connected the dots to reveal the larger tectonic story. The Denali Fault study has significant implications for ...

Tectonic Therapeutic shares doubled ... company said that in the overall study population, TX45 achieved a 17.9% reduction in pulmonary capillary wedge pressure, an endpoint known to correlate ...